{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:43:12Z","timestamp":1790239392825,"version":"4.1.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T00:00:00Z","timestamp":1468972800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s00280-016-3112-9","type":"journal-article","created":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T23:46:59Z","timestamp":1468972019000},"page":"559-566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network"],"prefix":"10.1007","volume":"78","author":[{"given":"Sumitra","family":"Shantakumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth L.","family":"Nordstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Djousse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan A.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy H.","family":"Fraeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrthe","family":"van Herk-Sukel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanenne","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,20]]},"reference":[{"key":"3112_CR1","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.ejca.2015.03.019","volume":"51","author":"T Powles","year":"2015","unstructured":"Powles T, Bracarda S, Chen M, Norry E, Compton N, Heise M, Hutson T, Harter P, Carpenter C, Pandite L, Kaplowitz N (2015) Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients. Eur J Cancer 51:1293\u20131302","journal-title":"Eur J Cancer"},{"key":"3112_CR2","unstructured":"GlaxoSmithKline (2010) Votrient (pazopanib) tablets prescribing information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/022465s018lbl.pdf . Accessed 21 Oct 2014"},{"issue":"2","key":"3112_CR3","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2302\/kjm.61.47","volume":"61","author":"Y Kubota","year":"2012","unstructured":"Kubota Y (2012) Tumor angiogenesis and anti-angiogenic therapy. Keio J Med 61(2):47\u201356","journal-title":"Keio J Med"},{"issue":"6","key":"3112_CR4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/bcp.12231","volume":"77","author":"R Iacovelli","year":"2014","unstructured":"Iacovelli R, Palazzo A, Procopio G, Santoni M, Trenta P, De Benedetto A, Mezi S, Cortesi E (2014) Incidence and relative risk of hepatic toxicity in patients treated with antiangiogenic tyrosine kinase inhibitors for malignancy. Br J Clin Pharmacol 77(6):929\u2013938","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"3112_CR5","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3109\/0284186X.2013.782103","volume":"52","author":"S Kapadia","year":"2013","unstructured":"Kapadia S, Hapani S, Choueiri TK, Wu S (2013) Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. Acta Oncol 52(6):1202\u20131212","journal-title":"Acta Oncol"},{"issue":"7","key":"3112_CR6","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2010.32.5977","volume":"29","author":"NE Kemeny","year":"2011","unstructured":"Kemeny NE, Jarnagin WR, Capanu M, Fong Y, Gewirtz AN, Dematteo RP, D\u2019Angelica MI (2011) Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol 29(7):884\u2013889","journal-title":"J Clin Oncol"},{"issue":"5","key":"3112_CR7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427\u2013434","journal-title":"N Engl J Med"},{"issue":"22","key":"3112_CR8","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584\u20133590","journal-title":"J Clin Oncol"},{"issue":"5","key":"3112_CR9","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S1499-3872(12)60209-4","volume":"11","author":"X Zhang","year":"2012","unstructured":"Zhang X, Yang XR, Huang XW, Wang WM, Shi RY, Xu Y, Wang Z, Qiu SJ, Fan J, Zhou J (2012) Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int 11(5):458\u2013466","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"3112_CR10","unstructured":"Pfizer Laboratories (2011) Sutent (sunitinib) prescribing information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021938s13s17s18lbl.pdf . Accessed 13 July 2015"},{"key":"3112_CR11","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/hep.20081","volume":"39","author":"A Reuben","year":"2004","unstructured":"Reuben A (2004) Hy\u2019s law. Hepatology 39:574\u2013578","journal-title":"Hepatology"},{"key":"3112_CR12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/pds.1211","volume":"15","author":"R Temple","year":"2006","unstructured":"Temple R (2006) Hy\u2019s law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 15:241\u2013243","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3112-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3112-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3112-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T14:46:11Z","timestamp":1498315571000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3112-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,20]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["3112"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3112-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,20]]}}}